|
286 Companies |
|
367 Products |
|
367 Products |
|
179 Mechanisms of Action |
|
18 Trials |
|
3665 News |
|
| «12...7891011121314151617...7778» |
- ||| temozolomide / Generic mfg.
Trial completion, Trial primary completion date, Monotherapy: Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=1804, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2016
- || vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Trial primary completion date: A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Nov 15, 2016
P1, N=70, Active, not recruiting, Sponsor: Tocagen Inc.
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial termination, Trial primary completion date: SRS (Stereotactic Radiosurgery) Plus Ipilimumab (clinicaltrials.gov) - Nov 15, 2016
P1, N=4, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jul 2016 --> Jul 2017 N=30 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; Local IRB required us to submit amendment as a separate study.
- | Phase classification, IO biomarker: Efficacy Study of IL-21 to Treat Metastatic Melanoma (clinicaltrials.gov) - Nov 14, 2016
P2a, N=54, Completed, Sponsor: Novo Nordisk A/S
N=30 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; Local IRB required us to submit amendment as a separate study. Phase classification: P2 --> P2a
- hydroxychloroquine / Generic mfg.
Enrollment closed, Trial primary completion date: A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) (clinicaltrials.gov) - Nov 8, 2016
P2, N=54, Active, not recruiting, Sponsor: University College, London
Phase classification: P2 --> P2a Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Oct 2016
- Trial suspension, IO biomarker, Metastases: Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma (clinicaltrials.gov) - Nov 8, 2016
P1, N=24, Suspended, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Oct 2016 Recruiting --> Suspended
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Nov 2, 2016
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Suspended Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017
- paxalisib (GDC-0084) / Kazia, SoVarGen, QIMR Berghofer Medical Research Institute
Enrollment change: A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma (clinicaltrials.gov) - Nov 2, 2016
P1, N=29, Completed, Sponsor: Genentech, Inc.
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017 N=47 --> 29
- | Tabrecta (capmatinib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Enrollment closed, Enrollment change: Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Nov 2, 2016
P1/2, N=42, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=47 --> 29 Recruiting --> Active, not recruiting | N=63 --> 42
- Avastin (bevacizumab) / Roche
Trial completion: ARTE: Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma (clinicaltrials.gov) - Nov 1, 2016
P2, N=75, Completed, Sponsor: University of Zurich
Recruiting --> Active, not recruiting | N=63 --> 42 Active, not recruiting --> Completed
- ||| crenolanib (ARO-002) / AROG
Trial completion: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - Nov 1, 2016
P1, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- epacadostat (INCB024360) / Incyte
Trial primary completion date, IO biomarker, Metastases: Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - Nov 1, 2016
P2, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Oct 2016 --> May 2017
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, ITC-6146RO / IntoCell
Enrollment closed, Enrollment change: Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors (clinicaltrials.gov) - Nov 1, 2016
P1, N=1, Active, not recruiting, Sponsor: Edward Ziga
Trial primary completion date: Oct 2016 --> May 2017 Recruiting --> Active, not recruiting | N=20 --> 1
- |||| dianhydrogalactitol (VAL-083) / Valent Tech
Trial completion: Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Oct 31, 2016
P1/2, N=55, Completed, Sponsor: DelMar Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=20 --> 1 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Nevus Doctor Clinical Decision Support (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=49, Completed, Sponsor: University Hospital of North Norway
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 49
- Provecta (rose bengal sodium) / Provectus
Trial primary completion date: Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study (clinicaltrials.gov) - Oct 27, 2016
P1, N=15, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed | N=100 --> 49 Trial primary completion date: Dec 2016 --> Dec 2015
- Inlyta (axitinib) / Pfizer
Trial primary completion date: A Study of Axitinib in Advanced Carcinoid Tumors (clinicaltrials.gov) - Oct 26, 2016
P2, N=30, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Dec 2016 --> Dec 2015 Trial primary completion date: Dec 2016 --> Jun 2017
- || depatuxizumab mafodotin (ABT-414) / AbbVie
Trial primary completion date: Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (clinicaltrials.gov) - Oct 26, 2016
P1, N=196, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jan 2017 --> May 2017
- |||| TVI-Brain-1 / TVAX Biomedical
Trial completion: Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma (clinicaltrials.gov) - Oct 25, 2016
P2, N=86, Completed, Sponsor: TVAX Biomedical
Trial primary completion date: Jan 2017 --> May 2017 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors (clinicaltrials.gov) - Oct 25, 2016
P1, N=18, Completed, Sponsor: Pediatric Brain Tumor Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Oct 21, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015 N=46 --> 30
- ITC-6146RO / IntoCell
Trial completion, Trial primary completion date: MET-PET for Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 21, 2016
P0, N=20, Completed, Sponsor: Massachusetts General Hospital
N=46 --> 30 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2016
- Biomarker, Trial completion, Metastases: AMMAM: Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=22, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2016 Active, not recruiting --> Completed
- | Signifor (pasireotide) / Recordati
Trial completion, Enrollment change, Trial primary completion date: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Oct 19, 2016
P1, N=22, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Trial primary completion date: Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation (clinicaltrials.gov) - Oct 19, 2016
P2, N=25, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Nov 2013
- Erivedge (vismodegib) / Roche
Trial primary completion date: Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=38, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Nov 2013 Trial primary completion date: Apr 2017 --> Apr 2018
- Trial completion, Trial primary completion date: In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer (clinicaltrials.gov) - Oct 18, 2016
P1, N=24, Completed, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Aug 2014
- |||| temozolomide / Generic mfg.
Trial primary completion date: EF-14: Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Oct 18, 2016
P3, N=700, Active, not recruiting, Sponsor: NovoCure Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Aug 2014 Trial primary completion date: Jul 2016 --> Dec 2016
- Trial completion, Trial primary completion date: Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Oct 17, 2016
P1, N=50, Completed, Sponsor: John Sampson
Trial primary completion date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2014
- temozolomide / Generic mfg.
Trial completion, Enrollment change: INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study (clinicaltrials.gov) - Oct 17, 2016
P1/2, N=12, Completed, Sponsor: Universit
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2014 Recruiting --> Completed | N=18 --> 12
- temozolomide / Generic mfg.
Trial primary completion date: IDEPREG: Image-derived Prediction of Response to Chemo-radiation in Glioblastoma (clinicaltrials.gov) - Oct 17, 2016
P=N/A, N=44, Recruiting, Sponsor: Rigshospitalet, Denmark
Recruiting --> Completed | N=18 --> 12 Trial primary completion date: Nov 2016 --> Feb 2017
- || dasatinib / Generic mfg.
Trial primary completion date: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Jun 2015 --> Dec 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Oct 13, 2016
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Sep 2016 --> Jun 2017
- |||| Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date: Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 12, 2016
P2, N=111, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Sep 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2012 --> Dec 2013
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
Active, not recruiting --> Completed | Trial primary completion date: Oct 2012 --> Dec 2013 Active, not recruiting --> Completed | N=24 --> 12
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date: Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform (clinicaltrials.gov) - Oct 11, 2016
P1, N=36, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=24 --> 12 Trial primary completion date: Oct 2016 --> Apr 2017
- | Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion: Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 7, 2016
P1, N=30, Completed, Sponsor: Actelion
Trial primary completion date: Oct 2016 --> Apr 2017 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: SAFE-MILND: Minimally Invasive Groin Dissection for Melanoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=88, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Dec 2015
- decitabine / Generic mfg.
Trial completion: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=19, Completed, Sponsor: University of Louisville
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Dec 2015 Active, not recruiting --> Completed
- Kimmtrak (tebentafusp-tebn) / Immunocore
Enrollment change: IMCgp100 in Advanced Unresectable Melanoma (clinicaltrials.gov) - Oct 5, 2016
P0, N=1, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed N=20 --> 1
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
N=20 --> 1 Active, not recruiting --> Completed | N=30 --> 18
- trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Oct 3, 2016
P1, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=30 --> 18 Active, not recruiting --> Completed | N=80 --> 37 | Trial primary completion date: Oct 2016 --> Apr 2016
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors (clinicaltrials.gov) - Sep 30, 2016
P0, N=6, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | N=80 --> 37 | Trial primary completion date: Oct 2016 --> Apr 2016 Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jan 2017 --> May 2016
- Enrollment change, Trial withdrawal: C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression (clinicaltrials.gov) - Sep 28, 2016
P2/3, N=0, Withdrawn, Sponsor: Phoenix Molecular Imaging
Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jan 2017 --> May 2016 N=200 --> 0 | Suspended --> Withdrawn
- || temozolomide / Generic mfg.
Trial primary completion date: Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma (clinicaltrials.gov) - Sep 27, 2016
P2, N=140, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=200 --> 0 | Suspended --> Withdrawn Trial primary completion date: Aug 2016 --> Aug 2017
- Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial primary completion date: Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 26, 2016
P1, N=30, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Oct 2016 --> Jun 2017
- NanO2 (perflenapent) / NuvOx Pharma
Enrollment closed, Phase classification, Trial primary completion date: The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (clinicaltrials.gov) - Sep 26, 2016
P1b, N=25, Active, not recruiting, Sponsor: NuvOx Pharma Pty Ltd
Trial primary completion date: Oct 2016 --> Jun 2017 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Jun 2015 --> Sep 2017
- temozolomide / Generic mfg.
Trial completion, Trial primary completion date: O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy (clinicaltrials.gov) - Sep 23, 2016
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Jun 2015 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2010 --> Jul 2009
- Biomarker, Trial primary completion date, Metastases: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites (clinicaltrials.gov) - Sep 23, 2016
P2b, N=30, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: Dec 2010 --> Jul 2009 Trial primary completion date: Apr 2016 --> Dec 2018
- || Biomarker, Trial primary completion date, Monotherapy: Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib (clinicaltrials.gov) - Sep 23, 2016
P2, N=54, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2016 --> Dec 2018 Trial primary completion date: Feb 2016 --> Dec 2016